Pharma channel feed

Neu­rol­o­gists pass on Aduhelm again. Most agree with CMS de­ci­sion to lim­it cov­er­age, study finds

4 years ago
Marketing

Break­ing with past com­ments, FDA's Richard Paz­dur telegraphs rough road ahead for Lil­ly's Chi­na-de­vel­oped can­cer drug

4 years ago
FDA+

Gen­mab, Seagen want cer­vi­cal can­cer to be seen in new 'Ce­Me' cam­paign along with pa­tient ad­vo­cates

4 years ago
Marketing

In up­hold­ing Mar­tin Shkre­li's life­time ban, judge rules any state­ment he makes about phar­ma could be a vi­o­la­tion

4 years ago
People

Af­ter some lengthy de­lays, Sanofi gets the FDA's OK for a rare dis­ease drug

4 years ago
FDA+

Vas Narasimhan and Sev­erin Schwan each claimed pay pack­ets worth $12M+ for 2021

4 years ago

Bris­tol My­er­s' Caforio: CELMoDs have po­ten­tial to re­place Revlim­id and Po­m­a­lyst as block­busters start to lose ex­clu­siv­i­ty

4 years ago
R&D

With thou­sands of jobs on the chop­ping block, 'noth­ing's off the table' at Sanofi. What's stay­ing and what's go­ing?

4 years ago

Re­gen­eron looks to George Yan­copoulos' R&D arm — and part­ners — in hunt for its next big cash cows

4 years ago
R&D

SEC and FTC open two more in­ves­ti­ga­tions in­to Bio­gen's con­tro­ver­sial Alzheimer's drug ap­proval and mar­ket­ing prac­tices

4 years ago

Must-pass user fee deals: Bio­phar­ma com­pa­nies fund more than 80% of FDA's re­view staff, CDER head tells Con­gress

4 years ago
FDA+

Eli Lil­ly hits pause on Aduhelm ri­val do­nanemab as ex­ecs fret about Medicare's skep­ti­cal stance on Alzheimer's drug class

4 years ago
R&D

Roche re­gains pre-pan­dem­ic sales foot­ing, high­lights burst­ing pipeline — with one key fail­ure

4 years ago

All for one: Sanofi un­veils mod­ern new cor­po­rate brand — and bids adieu to Pas­teur and Gen­zyme names

4 years ago
Marketing

Bleed­ing cash from its Alzheimer's fran­chise, Bio­gen preps 'deals of all sizes' as rev­enue shriv­els

4 years ago

Opin­ion: A place­bo-con­trolled tri­al re­quire­ment from CMS will spell the end of Bio­gen's con­tro­ver­sial Alzheimer's drug

4 years ago

A rar­i­ty for ICER: Cost watch­dog says Covid-19 ther­a­peu­tics ap­pro­pri­ate­ly priced in the US

4 years ago
Coronavirus

Cod­ed cal­en­dar in­vites, covert emails and delet­ed doc­u­ments: Pfiz­er sues ex-em­ploy­ees for al­leged­ly steal­ing trade se­crets

4 years ago
People

UPenn sues Genen­tech over patent in­fringe­ment with four can­cer drugs

4 years ago

Ab­b­Vie's Gon­za­lez: Skyrizi and Rin­voq to be­come Hu­mi­ra 2.0 — while adding an in­di­ca­tion for atopic der­mati­tis

4 years ago
R&D

Vas Narasimhan re­veals a dis­ap­point­ing out­look for No­var­tis' gener­ics unit, while lay­ing out the phar­ma's M&A strat­e­gy

4 years ago

Point un­veils new In­dy site to shore up sup­ply chain in fight against prostate can­cer

4 years ago
Manufacturing

PhRMA goes on the of­fen­sive, at­tack­ing the WHO and putting the EU, UK, Aus­tralia and oth­ers on no­tice

4 years ago
R&D

Organon launch­es day-off cam­paign to en­cour­age busi­ness lead­ers to pri­or­i­tize wom­en's health

4 years ago
Marketing
First page Previous page 224225226227228229230 Next page Last page
A service from the Financial Times